Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NovaBay Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NBY
American
8731
https://novabay.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
- Apr 22nd, 2024 10:57 am
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
- Apr 19th, 2024 10:00 pm
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
- Apr 17th, 2024 10:59 am
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript
- Mar 27th, 2024 3:28 pm
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
- Mar 27th, 2024 1:57 pm
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
- Mar 26th, 2024 8:05 pm
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
- Mar 25th, 2024 10:38 pm
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
- Mar 14th, 2024 12:00 pm
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
- Mar 13th, 2024 11:00 am
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
- Jan 30th, 2024 2:00 pm
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
- Jan 9th, 2024 2:15 pm
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes
- Dec 6th, 2023 11:50 am
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript
- Nov 12th, 2023 1:33 pm
NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results
- Nov 9th, 2023 9:05 pm
NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023
- Nov 2nd, 2023 10:50 am
NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs
- Oct 11th, 2023 12:00 pm
NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
- Oct 2nd, 2023 10:50 am
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
- Sep 21st, 2023 1:35 pm
NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft
- Sep 14th, 2023 12:00 pm
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
- Sep 11th, 2023 12:00 pm
Scroll